XM no presta servicios a los residentes de Estados Unidos de América.
S
S

Sanofi


Noticias

Dealmakers expect bigger European private equity buyouts and more of them

ANALYSIS- Dealmakers expect bigger European private equity buyouts and more of them Number of $5bn plus deals more than doubled in year to date Uninvested cash has piled up Private equity investors press for returns through asset sales By Amy-Jo Crowley, Andres Gonzalez, Mathieu Rosemain and Anousha Sakoui LONDON, Oct 22 (Reuters) - Buyout fund CD&R's keenly awaited 16 billion euro ($17.36 billion) deal to take control of Sanofi's consumer health unit, could herald an upsurge in big private equi
S

British Business - Oct. 22

PRESS DIGEST-British Business - Oct. 22 Oct 21 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - British engineering company Ricardo RCDO.L said it is divesting its defence business as part of a five-year strategic shift to become an "engineering consultancy in environmental and energy transition".
M
O
P
S
V
V

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Secureworks, Atlantic Union Bankshares, Catalent, Viad Corp Updates: EQT AB, DNB, CITIC Ltd Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Monday: ** Cybersecurity firm Sophos, which is backed by private equity firm Thoma Bravo, said it will acquire Secureworks SCWX.O for $859 million in an all-cash deal to strengthen its cybersecurity offering for small, mid and enterprise customers.
M
S
U
D

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Oct 21 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 0930 GMT on Monday: ** China's state-owned CITIC Ltd 0267.HK has agreed to sell its 19.23% stake in Fast Food Holdings, the company behind McDonald's China and Hong Kong operations, to Trustar Fast Food Holdings for $430.3 million.
M
S
U

STOXX 600 finishes lower ahead of key earnings reports

UPDATE 2-STOXX 600 finishes lower ahead of key earnings reports For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Forvia jumps on supply deal with China's BYD, Xiaomi SAP, bank earnings in focus this week Updated at 1600 GMT By Paolo Laudani, Ankika Biswas and Johann M Cherian Oct 21 (Reuters) - European shares ended Monday's choppy session in the red ahead of a series of marquee corporate earnings, although stabilising oil prices buoyed
B
D
L
M
S
S
E
F
I
S
G

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Oct 21 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. FORVIA FRVIA.PA The company on Monday posted third-quarter sales , flagging some optimism linked to its operation in China. SANOFI SASY.PA The French company said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S.
S
F
N
U

Sanofi in exclusive talks with CD&R over sale of $17 bln Opella

UPDATE 3-Sanofi in exclusive talks with CD&R over sale of $17 bln Opella Opella has been valued at around 16 bln euros, Sanofi says Paris given guarantees on jobs and production, sources say Sanofi increases 2024 earnings per share guidance Adds state to take a seat on board in paragraph 2, shares in 9 By Dominique Patton PARIS, Oct 21 (Reuters) - French drugmaker Sanofi SASY.PA said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella t
S

Sanofi enters exclusive talks with CD&R for Opella sale

Sanofi enters exclusive talks with CD&R for Opella sale PARIS, Oct 21 (Reuters) - Sanofi SASY.PA said on Monday it had entered exclusive negotiations for the sale of a 50% controlling stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R). The French pharmceutical company said its Opella business has been valued at around 16 billion euros ($17.38 billion), or 14 times EBITDA in 2024, and French public investment bank Bpifrance is expected to take
S

Financial Times - Oct 21

PRESS DIGEST- Financial Times - Oct 21 Oct 21 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Public to be asked for suggestions on how to fix NHS - French state takes stake in Sanofi unit to smooth 15.5 billion euro ($16.84 billion) deal Overview UK health secretary Wes Streeting will on Monday launch a "national conversation" about the future of the National Health Service, which he
S

REUTERS NEWS SCHEDULE AT 6 a.m SGT / 6 p.m. ET

REUTERS NEWS SCHEDULE AT 6 a.m SGT / 6 p.m. ET Here are the top stories and upcoming coverage plans for Reuters text service as of 6 a.m SGT / 6 p.m. ET. For a full schedule of news and events, go to our editorial calendar on Reuters Connect . TOP STORIES GLOBAL ISRAEL-PALESTINIANS/ Lebanese flee as Israel warns of strikes on Hezbollah financial arm BEIRUT/CAIRO (Reuters)- Hundreds of Beirut residents fled their homes late on Sunday after Israel said it was preparing attacks on sites linked to t
B
B
M
N
S
T

Sanofi reaches deal on terms of sale of consumer health arm, say French government sources

UPDATE 1-Sanofi reaches deal on terms of sale of consumer health arm, say French government sources Adds details, background PARIS, Oct 20 (Reuters) - Sanofi SASY.PA on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French government sources said on Sunday.
S

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI

Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI PARIS, Oct 20 (Reuters) - France will take a stake in Sanofi SASY.PA 's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro newspaper that U.S. private equity firm Clayton Dubilier & Rice (CD&R) is to take a 51% stake in the company that makes of one of France's most-sold painkillers, Doliprane.
S

France corporate earnings week ahead

DIARY-France corporate earnings week ahead Oct 18 (Reuters) - Diary of France (.FCHI) corporate earnings for the week ahead FRANCE EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 24-Oct-2024 BMO DAST.PA Dassault Systemes SE Q3 2024 Dassault Systemes SE Earnings Release 24-Oct-2024 05:30 ORAN.PA Orange SA Q3 2024 Orange SA Earnings Release 25-Oct-2024 05:30 SASY.PA Sanofi SA Q3 2024 Sanofi SA Earnings Release ** All times are listed in AMC - 'After market close', or BMO - 'Before
D
O
S
F

Financial Times - Oct 18

PRESS DIGEST- Financial Times - Oct 18 Oct 18 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - EY slims workforce for first time in 14 years - Sanofi joins rivals investing in nuclear cancer treatment - EU considers including Elon Musk's business empire to calculate potential X fine - UK plans to place 'buy now, pay later' lenders under FCA rules - UK explores plans for new rail line as
S

Merck's RSV antibody for infants effective in reducing some types of infections in study (Oct 17)

CORRECTED-Merck's RSV antibody for infants effective in reducing some types of infections in study (Oct 17) Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory infections, not all lower respiratory infections Oct 17 (Reuters) - Merck MRK.N said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some types of respiratory syncytial virus (RSV)-associated infections in infants.
A
P
S
S

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Snam, BP, Novo Nordisk, Pony AI; Updates Zuora Oct 17 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: ** BP BP.L is considering selling a minority stake in its offshore wind business, according to four sources with knowledge of the matter, the latest effort by CEO Murray Auchincloss to scale back the energy company's focus on renewables.
E
L
S
S
S
P

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds: Zuora, LVMH, PAI Partners, CSN, Sanofi, PPG Industries, Fuji Soft Oct 17 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Thursday: ** Fuji Soft 9749.T founder and shareholder Hiroshi Nozawa said in a letter to the company, seen by Reuters, that he supports U.S.
L
S
S
P

Sanofi 'surprised' by PAI Partners' raised bid for Opella unit

UPDATE 3-Sanofi 'surprised' by PAI Partners' raised bid for Opella unit PAI Partners seeks to outbid CD&R for Opella stake Sanofi's revised bid valid until Sunday night, source says Company says new offer came outside regular process Unions fear job losses, call for strike at Sanofi's plants Updates with reaction from Sanofi to the new offer in paragraphs 1-6 PARIS, Oct 17 (Reuters) - French drugmaker Sanofi SASY.PA said on Thursday it was "surprised" by a renewed, higher offer for its consumer
S

PAI Partners makes higher offer for Sanofi's Opella, says Le Monde

PAI Partners makes higher offer for Sanofi's Opella, says Le Monde PARIS, Oct 17 (Reuters) - French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's SASY.PA consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival Clayton Dubilier & Rice (CD&R). Sanofi said last week it was in talks with CD&R for the sale of a 50% stake in Opella.
S

Sanofi, Orano Join Forces To Develop Next-Generation Radioligand Medicines

BRIEF-Sanofi, Orano Join Forces To Develop Next-Generation Radioligand Medicines Oct 17 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: SANOFI AND ORANO JOIN FORCES TO DEVELOP NEXT-GENERATION RADIOLIGAND MEDICINES SANOFI AND ORANO TO INVEST IN NEW ENTITY FOR RADIOLIGAND THERAPIES TO INVEST €300 MILLION FOR 16% STAKE IN NEW ENTITY Source text for E
S



Condiciones

Activos populares

Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.

Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.

Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.

Advertencia de riesgo: Su capital está en riesgo. Los productos apalancados pueden no ser adecuados para todos. Por favor, tenga en cuenta nuestra Declaración de riesgos.